Perioperative ADA Glycemic Targets
The American Diabetes Association recommends a perioperative blood glucose target range of 100–180 mg/dL (5.6–10.0 mmol/L) within 4 hours of surgery. 1
Target Range Rationale
The 100–180 mg/dL target represents the most current ADA guidance from 2024 1, which updated from the previous 80–180 mg/dL range used in earlier guidelines 2, 3, 4. This shift reflects accumulating evidence that:
- Tighter targets do not improve outcomes: Multiple reviews have consistently demonstrated that perioperative glycemic control stricter than 80–180 mg/dL does not improve surgical outcomes 5, 1
- Increased hypoglycemia risk: Stricter targets are associated with significantly more hypoglycemic episodes without clinical benefit 5, 1, 6
Key Perioperative Management Points
Preoperative Optimization
- A1C target for elective surgery: <8% (63.9 mmol/L) whenever possible 1
- Perform preoperative cardiac risk assessment for patients with high ischemic heart disease risk, autonomic neuropathy, or renal failure 1
Medication Management on Day of Surgery
Critical medication adjustments:
- SGLT2 inhibitors: Discontinue 3–4 days before surgery (mandatory to prevent euglycemic DKA) 1
- Metformin: Hold on day of surgery 1
- Other oral agents: Hold morning of surgery 1
- Basal insulin: Give 75–80% of long-acting analog dose OR 50% of NPH dose 1
- Insulin evening before surgery: Reduce by 25% to decrease hypoglycemia risk while maintaining target range 5, 1
Intraoperative Monitoring
- Monitor blood glucose every 2–4 hours while NPO 1
- Dose with short- or rapid-acting insulin as needed 1
- Do not use CGM alone for glucose monitoring during surgery 1
Insulin Strategy for Noncardiac Surgery
Basal-bolus insulin is superior to sliding scale alone: In noncardiac general surgery patients, basal insulin plus premeal short- or rapid-acting insulin coverage has been associated with improved glycemic outcomes and lower rates of perioperative complications compared with correction-only insulin without basal coverage 5, 1. This represents a critical distinction—reactive sliding scale regimens alone are inadequate.
Important Caveats
GLP-1 receptor agonists: There are limited data on their safe use perioperatively, particularly regarding delayed gastric emptying risk 1. Exercise caution and consider holding, though specific guidance is evolving.
Avoid overly aggressive targets: The evidence is clear that attempting to achieve glucose levels below 80 mg/dL perioperatively increases harm without benefit 5, 1, 6. The 100–180 mg/dL range balances hyperglycemia-related complications (infection, mortality, length of stay) against hypoglycemia risk.